Katarzyna Plata-Nazar

Dr. Katarzyna Plata-Nazar

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AKA. Kluk
A. Kluk
MSMałgorzata Sznitowska
Małgorzata Sznitowska
ABA. Brandt
A. Brandt
KSK. Sznurkowska
K. Sznurkowska
KPKatarzyna Plata-Nazar
Katarzyna Plata-Nazar
HKH. Kotlowska
H. Kotlowska

Verified
Journal Article
Open access
PDF file
MLMagdalena Lange
Magdalena Lange
KHKarin Hartmann
Karin Hartmann
MCMelody C. Carter
Melody C. Carter
FSFrank Siebenhaar
Frank Siebenhaar
IÁIván Álvarez-Twose
Iván Álvarez-Twose
Peter ValentPeter Valent
Peter Valent
Pediatric mastocytosis is a heterogeneous disease characterized by accumulation of mast cells in the skin and less frequently in other organs. Somatic or germline mutations in the KIT proto-oncogene are detected in most patients. Cutaneous mastocytosis is the most common form of the disease in children. In the majority of cases, skin lesions regress spontaneously around puberty. However, in few patients, mastocytosis is not a self-limiting disease, but persists into adulthood and can show signs of systemic involvement, especially when skin lesions are small-sized and monomorphic. Children with mastocytosis often suffer from mast cell mediator-related symptoms. Severe hypersensitivity reactions can also occur, mostly in patients with extensive skin lesions and blistering. In a substantial number of these cases, the triggering factor of anaphylaxis remains unidentified. Management of pediatric mastocytosis is mainly based on strict avoidance of triggers, treatment with H1 and H2 histamine receptor blockers, and equipment of patients and their families with epinephrine auto-injectors for use in severe anaphylactic reactions. Advanced systemic mastocytosis occurs occasionally. All children with mastocytosis require follow-up examinations. A bone marrow investigation is performed when advanced systemic mastocytosis is suspected and has an impact on therapy or when cutaneous disease persists into adulthood.

Verified
Journal Article
Open access
PDF file
KBKnut Brockkow
Knut Brockkow
KPKatarzyna Plata-Nazar
Katarzyna Plata-Nazar
MLMagdalena Lange
Magdalena Lange
Bogusław NedoszytkoBogusław Nedoszytko
Bogusław Nedoszytko
MNMarek Niedoszytko
Marek Niedoszytko
Peter ValentPeter Valent
Peter Valent
Mastocytosis is characterized by the pathological accumulation of mast cells (MC) in various organs. In these patients, MC may degranulate and thereby contribute to clinical symptoms, especially when a concomitant allergy is present. However, MC activation can not only be induced by high-affinity receptors for IgE, but also by anaphylatoxins, neuropeptides, IgG immune complexes, complement-components, drugs, products of bacteria or parasites, as well as physical factors such as heat, cold, vibration, stress, sun, or physical effort. Symptoms due to mediators released by activated MC may develop in adults suffering from systemic mastocytosis, but also evolve in children who usually have cutaneous mastocytosis (CM). Clinically, CM is otherwise characterized by typical brown, maculopapular skin lesions or mastocytoma associated with a positive Darier’s sign. Pruritus and flushing are common and blistering may also be recorded, especially in diffuse CM (DCM). Pediatric patients with mastocytosis may also have gastrointestinal, respiratory, and neurologic complaints. Although anaphylaxis is not a typical finding, pediatric patients with massive skin involvement and high tryptase levels have a relatively high risk to develop anaphylaxis. This paper reviews MC mediator-related symptoms and anaphylaxis in children with mastocytosis, with special emphasis on risk factors, triggers, and management.

1 March 2016 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
MLMagdalena Lange
Magdalena Lange
HŁH Ługowska-Umer
H Ługowska-Umer
MNMarek Niedoszytko
Marek Niedoszytko
BWBartosz Wasag
Bartosz Wasag
JLJ Limon
J Limon
Roman J. NowickiRoman J. Nowicki
Roman J. Nowicki
Mastocytosis comprises a heterogeneous group of disorders characterized by clonal, neoplastic proliferation of mast cells accumulating in on...

1 February 2011 in Pteridines
Verified
Journal Article
Open access
KPKatarzyna Plata-Nazar
Katarzyna Plata-Nazar
AJAgnieszka Jankowska
Agnieszka Jankowska
Neopterin is one of biochemical markers of immune activity, which seems to be useful in monitoring inflammatory diseases. Increased serum concentration of neopterin is observed in conditions with cell-mediated immune response involvement. In clinical practice, neopterin evaluation is applied in medical conditions such as: infectious diseases, oncology, rheumatology, transplantology, transfusiology, cardiology, neurology and many others. Neopterin can be detected in serum, urine, cerebrospinal fluid, synovial fluid, saliva, ascitic fluid, bile, pancreatic juice and gastric juice. In recently published studies, various non-specific indicators of inflammation such as neopterin, C-reactive protein, procalcitonin were compared and proved to be independently useful.

28 April 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
WNWojciech Nazar
Wojciech Nazar
KPKatarzyna Plata-Nazar
Katarzyna Plata-Nazar
KSKatarzyna Sznurkowska
Katarzyna Sznurkowska
ASAgnieszka Szlagatys-Sidorkiewicz
Agnieszka Szlagatys-Sidorkiewicz
Histamine intolerance is defined as a disequilibrium of accumulated histamine and the capacity for histamine degradation. This clinical term addresses a non-immunologically mediated pathology when histamine ingested with food is not particularly high, however its degradation is decreased. This paper aims to provide a narrative review on etiopathology, epidemiology, possible diagnostic algorithms and diagnostic challenges of histamine intolerance in children. The clinical picture of histamine intolerance in children is similar to that observed in adults apart from male predominance found in paediatric patients. Both in children and adults, a histamine-reduced diet is typically the treatment of choice. Diamine oxidase supplementation offers another treatment option. There is no symptom or test pathognomonic for histamine intolerance. Nevertheless, manifestations of chronic gastrointestinal symptoms, measurements of diamine oxidase deficits, positive results of histamine provocation tests and improvement in symptoms with histamine-reduced diet considerably increase the probability of histamine intolerance diagnosis. These factors have been included in the proposed diagnostic algorithm for histamine intolerance. In children histamine intolerance most likely co-occurs with allergies and bowel diseases, which creates an additional diagnostic challenge. As the evidence for children is poor further research is needed the determine epidemiology, validate diagnostic algorithms and establish possible treatment options regarding histamine intolerance.